1
Home
Companies

Arcellx

#3222

Rank

$3.56B

Marketcap

US United States

Country

Arcellx
Leadership team

Mr. Rami Elghandour (Chairman, CEO & Pres)

Mr. Neeraj P. Teotia (Chief Commercial Officer)

Dr. Christopher R. Heery M.D. (Chief Medical Officer)

Products/ Services
Biopharma, Biotechnology, Health Care, Life Science, Pharmaceutical
Number of Employees
50 - 100
Headquarters
Gaithersburg, Maryland, United States
Established
2015
Company Registration
SEC CIK number: 0001786205
Traded as
ACLX
Social Media
URL
https://arcellx.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
History

Arcellx was founded in 2019 by a team of highly experienced professionals in the biotech industry. With the support of leading medical and scientific advisors, we set out to develop and commercialize innovative cellular therapies. We have grown quickly, and our collection of scientific and clinical achievements continues to grow.

Mission
To develop innovative cellular therapies that enable cells to heal, and enable personalized care for each patient.
Vision
To be a leader in the development and commercialization of innovative cellular therapies that improve the lives of patients with cancer and other serious diseases.
Key Team

Ms. Michelle Lim Gilson (Chief Financial Officer)

Mr. Michael Dombeck M.B.A. (Chief Operating Officer)

Mr. Narinderjeet Singh M.S. (Chief Technical Officer)

Ms. Myesha Lacy (VP of Investor Relations)

Mr. David Tice Ph.D. (Chief Scientific Officer)

Ms. Maryam Abdul-Kareem J.D., M.S. (Gen. Counsel)

Ms. Kate Aiken (Chief People Officer)

Recognition and Awards
We have been awarded several prestigious awards, including the EUICC Breakthrough Award, the Pharma Technology Excellence Award, and the Agilent Innovator of the Year Award.
References

https://in.investing.com/equities/arcellx

https://finance.yahoo.com/quote/ACLX/profile?p=ACLX

https://www.crunchbase.com/organization/arcellx

https://sec.report/CIK/0001786205

https://companiesmarketcap.com/

https://arcellx.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Arcellx
Leadership team

Mr. Rami Elghandour (Chairman, CEO & Pres)

Mr. Neeraj P. Teotia (Chief Commercial Officer)

Dr. Christopher R. Heery M.D. (Chief Medical Officer)

Products/ Services
Biopharma, Biotechnology, Health Care, Life Science, Pharmaceutical
Number of Employees
50 - 100
Headquarters
Gaithersburg, Maryland, United States
Established
2015
Company Registration
SEC CIK number: 0001786205
Traded as
ACLX
Social Media
URL
https://arcellx.com